New hope for blood cancer patients: experimental combo aims to stop transplant complications
NCT ID NCT05120570
Summary
This study tested a new three-drug combination (PTCy, sirolimus, and VIC-1911) to prevent two major problems after a stem cell transplant: graft-versus-host disease (GVHD) and cancer relapse. It involved 16 adults with blood cancers like leukemia and lymphoma who received a high-dose transplant. The main goal was to find the safest and most effective dose of the new drug VIC-1911 to use with standard medications.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.